SMMT Stock Overview
A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Summit Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.00 |
| 52 Week High | US$33.89 |
| 52 Week Low | US$1.89 |
| Beta | -0.92 |
| 11 Month Change | -2.44% |
| 3 Month Change | 47.93% |
| 1 Year Change | 925.64% |
| 33 Year Change | 268.32% |
| 5 Year Change | 1,215.79% |
| Change since IPO | 94.36% |
Recent News & Updates
Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?
Nov 08
Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market
Oct 04Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Sep 19Recent updates
Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?
Nov 08Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market
Oct 04Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Sep 19Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)
Sep 09Summit Therapeutics May Have Further Upside From Here
Aug 03Summit Therapeutics Stock: Plunging Despite A Win?
May 31Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
May 06Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress
Jan 30We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely
Dec 29Summit Therapeutics slips on plans to terminate study for lead candidate
Oct 04Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio
Aug 17Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M
Aug 11Summit to explore additional trial for its bacteria-induced colon infection drug
Jul 14Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation
Apr 29Summit Therapeutics - Disappointing Data But Not An Outright Failure
Dec 23Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator
Jun 22Summit Therapeutics to join Russell 3000 Index
Jun 08Shareholder Returns
| SMMT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.7% | -7.5% | -1.2% |
| 1Y | 925.6% | 14.1% | 30.4% |
Return vs Industry: SMMT exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: SMMT exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| SMMT volatility | |
|---|---|
| SMMT Average Weekly Movement | 21.5% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SMMT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SMMT's weekly volatility has decreased from 42% to 21% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 105 | Bob Duggan | www.summittxinc.com |
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab.
Summit Therapeutics Inc. Fundamentals Summary
| SMMT fundamental statistics | |
|---|---|
| Market cap | US$14.75b |
| Earnings (TTM) | -US$196.68m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-75.0x
P/E RatioIs SMMT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SMMT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$196.68m |
| Earnings | -US$196.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 5.6% |
How did SMMT perform over the long term?
See historical performance and comparison